Here are the 10-K annual reports from OSI Systems Inc (OSIS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow OSIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OSIS filings page.
OSI Systems, Inc. (OSIS) filed its annual report describing a diversified business built around three divisions: Security (Rapiscan, S2 turnkey screening), Optoelectronics and Manufacturing (OSI Optoelectronics, OSI Electronics, Altaflex, PFC), and Healthcare (Spacelabs patient monitoring, cardiology, connected care and clinical decision support).
The company serves homeland security, defense, aerospace, industrial and healthcare markets globally, with manufacturing and engineering across the Americas, Europe and Asia and an emphasis on vertical integration, software platforms and SaaS inspection solutions. As of June 30, 2026, OSI reported a consolidated backlog of about $1.9 billion, direct Security-division sales to the U.S. Government of $207.3 million, and a non‑affiliate equity market value of $4.02 billion. The workforce totaled 7,806 employees worldwide, with 42.2% of the global workforce female and 52.7% of the U.S. workforce ethnically diverse.
OSI Systems, Inc. presents an annual 10-K with several operational, regulatory, and financial disclosures. Management concluded internal control over financial reporting was effective as of June 30, 2025. The company maintains annual third-party cybersecurity audits and an ISO/IEC 27001 certification process. EU Medical Device Regulation changes broaden device scope and require expanded clinical evaluation and a designated compliance officer. Capital structure notes include 16,825,913 shares outstanding as of August 18, 2025 and a 2.25% convertible senior note due 2029 with a conversion price of $191.98. Concentration risk exists in the Security division receivables (one customer ~42% at June 30, 2025). The company disclosed a Department of Justice subpoena related to a former employee and reported transaction gains/(losses) of approximately $2.0M, ($5.1M), and ($12.7M) for fiscal 2023–2025. Other notable items: performance bond exposure of ~$104M, unrecognized tax benefits of $15.1M, and $12.7M of restricted stock unit compensation to be recognized over ~2.2 years.